Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Targeting the BCL-2 BH4 Domain For Cancer Therapy
FY 2013-14
Summary
One of the most common problems that oncologists battle in the clinic is the emergence of cancer resistance to chemo- and radiotherapy. Research into the mechanisms underlying this resistance has uncovered a common pathway that is deregulated in most cancers, allowing them to withstand the onslaught of radiation and toxic drugs. This pathway, known as programmed cell death or apoptosis, is regulated by the BCL-2 protein family. In normal cells, a delicate balance exists between members of the BCL-2 family that promote or inhibit apoptosis such as BAX and BCL-2, respectively. However, in most cancers this balance is disrupted by the overexpression of antiapoptotic BCL-2 proteins resulting in decreased drug responses and poor overall patient survival. Previous drug development efforts have focused on targeting a surface groove found on the antiapoptotic BCL-2 proteins that allows them to sequester and inhibit proapoptotic BCL-2 proteins like BAX. However, recent data points to a previously uncharacterized interaction between a component of BCL-2, called the BH4 domain, and BAX. I determined that the BH4 domain also contributes to inhibiting cell death by binding to and blocking BAX. Therefore, this interaction is an attractive target for cancer drug discovery because disrupting the BH4/BAX interaction would help reactivate the death pathway in cancer cells. Using new research tools from the various disciplines of chemical, molecular and structural biology, I propose to develop a potent and selective agent to disrupt this mode of cell death inhibition. Since BCL-2 overexpression is found in many types of cancer, this novel drug strategy has the potential for broad application as a monotherapy or in combination with other cancer therapies. By targeting the BCL-2 BH4/BAX interaction, I hope to undermine a key cancer resistance mechanism and bring the hope of remission to cancer patients desperately seeking new treatments to combat relapsed and refractory disease.
Department
Program
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
307817
Name
Mourtada Rida
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Targeting the BCL-2 BH4 Domain For Cancer Therapy
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
Alpha-Helix; Apoptosis; Bax; Bcl-2; Programmed Cell Death; Stapled Peptides; Targeted Therapy
Abstract
One of the most common problems that oncologists battle in the clinic is the emergence of cancer resistance to chemo- and radiotherapy. Research into the mechanisms underlying this resistance has uncovered a common pathway that is deregulated in most cancers, allowing them to withstand the onslaught of radiation and toxic drugs. This pathway, known as programmed cell death or apoptosis, is regulated by the BCL-2 protein family. In normal cells, a delicate balance exists between members of the BCL-2 family that promote or inhibit apoptosis such as BAX and BCL-2, respectively. However, in most cancers this balance is disrupted by the overexpression of antiapoptotic BCL-2 proteins resulting in decreased drug responses and poor overall patient survival. Previous drug development efforts have focused on targeting a surface groove found on the antiapoptotic BCL-2 proteins that allows them to sequester and inhibit proapoptotic BCL-2 proteins like BAX. However, recent data points to a previously uncharacterized interaction between a component of BCL-2, called the BH4 domain, and BAX. I determined that the BH4 domain also contributes to inhibiting cell death by binding to and blocking BAX. Therefore, this interaction is an attractive target for cancer drug discovery because disrupting the BH4/BAX interaction would help reactivate the death pathway in cancer cells. Using new research tools from the various disciplines of chemical, molecular and structural biology, I propose to develop a potent and selective agent to disrupt this mode of cell death inhibition. Since BCL-2 overexpression is found in many types of cancer, this novel drug strategy has the potential for broad application as a monotherapy or in combination with other cancer therapies. By targeting the BCL-2 BH4/BAX interaction, I hope to undermine a key cancer resistance mechanism and bring the hope of remission to cancer patients desperately seeking new treatments to combat relapsed and refractory disease.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mourtada, Rida
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~